1 Big Growth Driver Withdrawn

Don’t let the headlines fool you, Celgene’s (Nasdaq: CELG  ) application to market Revlimid, as a maintenance treatment for newl- diagnosed multiple myeloma patients, was rejected by the EU's Committee for Medicinal Products for Human Use, or CHMP.

Technically, the biotech withdrew its application, but that's just standard operating procedure in the EU when a company figures out that its drug is going to be rejected if it doesn't pull the application. Recently, Novartis (NYSE: NVS  ) withdrew its application to expand the indication for Exelon and Prometax. Ditto for GlaxoSmithKline's (NYSE: GSK  ) Tyverb and Pfizer's (NYSE: PFE  ) Macugen.

Companies withdraw their applications because, when a negative opinion by CHMP is handed down, the European Medicines Agency publishes a summary of the negative opinion, which might help rivals. By withdrawing the application, Celgene avoided having that information made public.

In the U.S., the Food and Drug Administration doesn’t publish information on drugs that aren't approved, so there's no need to withdraw an application, except in rare situations, like when Cell Therapeutics (Nasdaq: CTIC  ) withdrew its application for pixantrone  because it needed more time to prepare for an advisory committee meeting.

The problem for Revlimid seems to trace back to its potential to cause cancer. Ironic, isn't it? A cancer drug increasing a cancer risk, but that's what Celgene saw in its trials: patients taking Revlimid had a higher incidence of secondary cancers than those that got placebo. It isn't clear, however, whether the drug is causing cancer, or if it's just that the patients are living longer, giving them more opportunity to acquire a secondary cancer.

CHMP wants more data supporting the idea that Revlimid helps patients live longer by delaying the reoccurrence of multiple myeloma, despite the fact that some patients get secondary cancers. Celgene has three clinical trials from which to derive long-term data, and plans to look every three months to see if there's enough data to reapply.

In the U.S., Celgene plans to delay submitting its marketing application to use Revlimid as a maintenance therapy until next year. The U.S. delay isn't as big a deal as the EU one, because stateside doctors can, and do, currently use the drug off label as a maintenance therapy. In the EU, there's virtually no off-label use, making it an important opportunity for Celgene to increase sales.

Unfortunately, that growth driver has been withdrawn for now.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool's disclosure policy has been updated but never withdrawn.
 
We Fools may not all hold the same opinions, but we all believe that
considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 22, 2012, at 8:26 AM, OBAMABB wrote:

    Still Bashing CTIC I see whats that make 60 times in the last six months?

    The Best Chemo drug to come along in 10 years yet you thieves Bash it!

    Posting yesterdays loss just proves you are a basher rag nothing more nothing less.

    Pixantrone has a 63% S/R 2 years instead of months a 24% C/R over Dox yet not one word from you!

    or a 92% (chop) S/R 2 years instead of months to live yet you keep Bashing!

    You Better hope you never need it!

  • Report this Comment On June 22, 2012, at 7:26 PM, bobleelaw wrote:

    Good read, informative, thank you.

    As to the depressing of CTIC comment by obamabb, I have decided that as bad as the Technical Signals may look for that stock, I am seeing some BULLISH outlooks on the way.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1920836, ~/Articles/ArticleHandler.aspx, 9/17/2014 5:58:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement